GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Capitalism and greed gave Britain its vaccine success, PM Johnson says

Tue, 23rd Mar 2021 21:51

* Johnson tries to row back from gaffe on greed

* Praises capitalism in vaccine lead

* UK state money developed the Oxford vaccine

* Communist China moved fast to develop a vaccine
(Adds context on Oxford vaccine)

By Costas Pitas

LONDON, March 24 (Reuters) - Capitalism and greed gave
Britain its success in vaccinating its population, Prime
Minister Boris Johnson told lawmakers in a closed meeting, a
remark that could rile up Brussels at a time when Britain faces
an EU threat to block vaccine imports.

"The reason we have the vaccine success is because of
capitalism, because of greed my friends," The Sun newspaper
quoted Johnson as telling Conservative lawmakers on a Zoom
meeting on Tuesday evening.

Johnson then tried to row back and said: "Actually I regret
saying it" and asked lawmakers repeatedly to "forget I said
that".

Britain has so far mounted the fastest COVID-19 vaccine
programme of any big country. But it now finds its programme
threatened by the EU, which has been far slower in rolling out
vaccines and faces a third wave of infections.

The European Commission is expected on Wednesday to extend
powers to block exports, a move that could hit supply of doses
bound for Britain. Johnson's remarks come after a week in which
British ministers have tried to calm the row.

Downing Street declined to comment on Johnson's remarks when
contacted by Reuters, but unidentified sources gave the BBC a
bizarre array of explanations.

The greed comment, according to the BBC's political editor
Laura Kuenssberg, was apparently a joke about one of his cabinet
colleagues, Chief Whip Mark Spencer, who was gobbling a cheese
and pickle sandwich while the prime minister spoke.

Johnson, Home Secretary Priti Patel said, was talking about
the success of pharmaceutical companies in developing a vaccine
shot in record time.

"Clearly the prime minister was actually referring to the
work that has taken place with pharmaceutical companies and how
we have led the way really in this vaccine development," said
Patel, who was not in the meeting.

Britain was one of several countries that developed a
COVID-19 vaccine shot in record time: the shot developed by
Oxford University and AstraZeneca was approved for use
on Dec. 30 by the British medicines regulator.

The British government helped fund the research, and
AstraZeneca has promised to market it on a not-for-profit basis.

Other vaccines around the world have been developed with
state funding, from Communist China and former communist Russia
to the capitalist United States.
(Reporting by Costas Pitas and Guy Faulconbridge; Editing by
Steve Orlofsky, Rosalba O'Brien, Kate Holton and Peter Graff)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.